Clarity Pharmaceuticals Receives First FDA Breakthrough Therapy Designation for Prostate Cancer Imaging

First FDA Breakthrough Therapy Designation in PSMA PET Imaging Granted to Cu-64 SAR-bisPSMA

On November 12, 2026, Clarity Pharmaceuticals, a clinical-stage company focused on radiopharmaceutical innovation, celebrated a remarkable achievement: the United States Food and Drug Administration (FDA) granted Breakthrough Therapy designation to their groundbreaking product, 64Cu-SAR-bisPSMA. This designation is a vital step intended to accelerate the development and review of drugs that address serious health concerns, in this case, for men facing prostate cancer with suspected recurrence caused by elevated levels of prostate-specific antigen (PSA).

The breakthrough therapy designation is more than just a label; it highlights a commitment from the FDA to expedite processes for drugs that offer a significant improvement over existing treatments based on preliminary clinical evidence. For Clarity Pharmaceuticals, this designation is a game-changer, as it focuses on an innovative imaging process that could redefine how prostate cancer recurrence is detected.

Understanding the Breakthrough Therapy Designation

This designation is crucial for pharmaceuticals in the early stages of development. It is designed to ensure the swift availability of promising drugs, enabling them to reach the market more quickly and safely. The benefits include not only expedited processes but also enhanced guidance from the FDA, ensuring that developers receive proactive support throughout the drug development lifecycle.

Clarity secured this milestone based on data from Phase II Co-PSMA trials and the Phase I/II COBRA trials, alongside real-world evidence demonstrating that their product outperforms standard care PSMA PET imaging techniques used for prostate cancer patients with biochemical recurrence.

Significance for Patients with Prostate Cancer

Prostate cancer is a widespread health issue, often leading to severe complications if detected late. The need for accurate diagnostic tools is paramount, as existing products have limitations, often failing to detect metastases in patients with lower PSA levels. Current leading PSMA PET agents show low detection sensitivity, with FDA-approved accuracy rates as low as 36% for patients with PSA levels below 0.5 ng/mL.

In contrast, Clarity's 64Cu-SAR-bisPSMA demonstrated a detection rate of 78% in similar patient cohorts. This substantial increase in diagnostic accuracy could lead to more effective and timely treatment plans, ultimately improving management outcomes for those battling recurrence of prostate cancer.

The Innovative SAR Technology Behind 64Cu-SAR-bisPSMA

At the heart of this breakthrough is Clarity's proprietary SAR Technology. This advanced platform efficiently binds copper isotopes into its specialized chelator, preventing dangerous leakage into the body, which has been a significant hurdle for earlier clinical applications. Copper-64, featured in this imaging modality, provides extended half-life capabilities—ensuring effective imaging even hours post-injection. Moreover, the unique bivalent structure of bisPSMA allows improved targeting of PSMA, thus enhancing detection rates.

Ongoing and Future Trials

Clarity is currently advancing into Phase III registrational trials for 64Cu-SAR-bisPSMA, branded AMPLIFY and CLARIFY. Both trials have completed recruitment, and topline results are expected in the first half of 2027. These trials aim to validate the efficiency and effectiveness of 64Cu-SAR-bisPSMA as a new standard for prostate cancer imaging.

Dr. Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, expressed the significance of receiving the first-ever Breakthrough Therapy designation in the realm of PSMA PET imaging. He emphasized the potential impact of improved detection capabilities on clinical management, stating, “This designation marks a major milestone in our prostate cancer program and emphasizes the urgent need for better diagnostic tools in this field.”

Conclusion

The FDA Breakthrough Therapy designation for 64Cu-SAR-bisPSMA represents a significant leap forward in prostate cancer management and imaging. As Clarity Pharmaceuticals forges ahead with trials, this innovative approach has the potential to alter the landscape of prostate cancer diagnostics, improving patient outcomes and paving the way for future therapeutic advancements in cancer care.